This expansion, announced by New York Governor Kathy Hochul, is supported by New York State through the state’s economic development agency, Empire State Development (ESD). The state government
The collaboration is set to address the issue of relapse in patients undergoing treatment with conventional anti-CD19 CAR T-cell therapies through the use of TriCAR-T immunotherapy. As per
The funding round was led jointly by ARTIS Ventures and Wing VC, with contributions from a consortium of investors including Alexandria Venture Investments, Fusion Fund, OMX Ventures, Civilization
The BLA seeks approval for the use of subcutaneous nivolumab as a monotherapy, as maintenance therapy after treatment with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with
The financing round is co-led by 8VC and DCVC Bio, with contributions from Samsung Life Science Fund, The Children’s Hospital of Philadelphia Foundation, Benjamin Franklin Technology Partners, Modi
According to Korea Biomedical Review (KBR), the company’s flagship autoimmune disease treatment, called ‘Remsima’, has secured a substantial tender from the Peruvian Workers’ Insurance System (EsSalud). This tender
This partnership will utilise Scenic Biotech’s Cell-Seq platform to identify target biology for indication selection and expansion. Under the new agreement, Scenic Biotech will receive an upfront payment,
This approval marks a significant milestone as TIVDAK becomes the first antibody-drug conjugate (ADC) with proven overall survival data to receive such endorsement in this patient group. The
RAG-01 is a new therapy aimed at treating non-muscle invasive bladder cancer (NMIBC). This regulatory milestone enables the commencement of clinical trials in the US. NMIBC accounts for
As part of the new collaboration, the two companies will work together to co-create the candidate for the oncology target, leveraging PepMetics technology. Once the development candidate is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.